Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (376 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomaheartequal tocancerhours
  Phrases that lowered it: participantsdayliverinvestigatemg
• Sponsor's past termination rate: 18.4% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 174 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 19.7% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 76.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 130131 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 25193 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy NCT03302247 · started 2018 · scored riskier than 98% of active trials terminated
• VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) NCT04166383 · started 2020 · scored riskier than 83% of active trials terminated
• Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) NCT04057365 · started 2019 · scored riskier than 99% of active trials terminated
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma NCT03274258 · started 2018 · scored riskier than 75% of active trials terminated
• Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies NCT04214418 · started 2020 · scored riskier than 90% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.